|Day Low/High||25.86 / 26.11|
|52 Wk Low/High||25.76 / 35.04|
Results from the international, multicenter Child Hood Asthma Safety and Efficacy (CHASE) 3 Phase III study showed that SYMBICORT ® (budesonide/formoterol fumarate dihydrate) Inhalation Aerosol 80/4.
A sale or spinoff of this business will likely get the attention of competitors that want to increase their over-the-counter product units.
European bond markets hit hard as traders brace for inflation rise, blunting two-day 'Trump rally'.
European stocks are trading higher Thursday, after massive gains in Japan, but government bond yields are also rising fast.
AstraZeneca saw a 44% decline in Crestor sales as generic brands challenge the company's cholesterol blockbuster.
U.S. stock futures rise and the Dow is poised to open at a record Thursday as equities continue their rally following Donald Trump's win in the U.S. presidential election.
Stock futures are tumbling Wednesday but are well off their lows as Republican Donald Trump is elected the next president of the United States in a surprising victory.
The threat of a government clampdown on drug prices is off the table with Clinton's defeat, while wider support for defensive stocks helped push pharmaceuticals higher.
Gilead Sciences is nearing the completion of two phase III studies of the Jak inhibitor momelotinib in myelofibrosis, a disease affecting bone marrow.
Cramer shares his views on the rise of the stay-at-home consumer. Starbucks, Apple and Facebook are among the stocks discussed.
For the week of November 7, all eyes will be on Tuesday's presidential election.
The biotech company cancelled its conference appearance and took its time filing its Form 10-Q with the Securities and Exchange Commission.
Stocks in the health care sector seem to have no underpinnings whatsoever.
AstraZeneca today announced data from the second season of its SENTINEL1 study, the largest study ever to examine laboratory-confirmed respiratory syncytial virus hospitalizations (RSVH) among US preterm infants 29-35 weeks...
Jim Cramer comments on AstraZeneca's recent success in a cancer drug trial.
AstraZeneca's Lynparza significantly delayed the recurrence of tumors in patients with ovarian cancer compared to a placebo, according to results from a phase III study announced by the company Wednesday.
AstraZeneca today announced positive results from the Phase III SOLO-2 trial designed to determine the efficacy of LYNPARZA TM (olaparib) tablets (300mg twice daily) as a monotherapy for the maintenance treatment of...
Here are Friday's top research calls, including upgrades for ConAgra Foods and Domino's Pizza, and downgrades for Ameriprise and Lear.
TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,300 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: DNKN, TCP Downgrades: AZN Initiations: None Read on to get TheStreet Quant Ratings' detailed report:
Tesaro is soaring, but the company is overvalued if regulators decide to grant marketing clearance for niraparib only in a smaller, more restricted population of ovarian cancer patients.
AstraZeneca today announced data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg compared to anastrozole 1mg in the 1st line treatment of postmenopausal...
Takeover speculation that had fueled the recent rise in Clovis' stock price looks to be subsiding.
Chi-Med may be pressing ahead with a series of late-stage oncology drug trials, but it is anything but a one-trick pony biotech company.
AstraZeneca today announced new data demonstrating that respiratory syncytial virus hospitalization (RSVH) rates increased significantly during the 2014-2015 RSV season among US infants <3 months of age born at 29-34...
Britain's Brexit fortunes remain difficult to assess as markets offer mixed-signals on EU departure.
A cancer research meeting beginning on Friday will provide investors with an opportunity to inspect updated clinical data on two competing PARP inhibitors from Clovis Oncology and Tesaro.